FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD‐L1 Expression and Cell Proliferation (Adv. Sci. 29/2022)

Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outc...

Full description

Saved in:
Bibliographic Details
Published in:Advanced science 2022-10, Vol.9 (29), p.n/a
Main Authors: Madhi, Hamadi, Lee, Jeon‐Soo, Choi, Young Eun, Li, Yan, Kim, Myoung Hee, Choi, Yongdoo, Goh, Sung‐Ho
Format: Article
Language:English
Subjects:
Cover Picture
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy The FOXM1 inhibitor, thiostrepton, inhibits the expression of programmed death‐ligand 1 (PD‐L1) on the surface of cancer cells, allowing cytotoxic T cells to recognize cancer cells. Combination of thiostrepton and an immune checkpoint inhibitor significantly improves immunotherapy outcomes in immune‐resistant lung tumors. More details can be found in article number 2202702 by Yongdoo Choi, Sung‐Ho Go, and co‐workers.
ISSN:2198-3844
2198-3844
DOI:10.1002/advs.202270183